Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

americanpharmaceuticalreviewDecember 04, 2020

Tag: PY314 , Pionyr Immunotherapeutics , Tumor

PharmaSources Customer Service